The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
NCT: NCT06152653 · ACTIVE_NOT_RECRUITING
Brief Summary
The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure. * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on lung function than delivery of NAC without positive pressure. Participants will be assigned (in a single blind design) to the NAC via jet nebulizer group or the NAC via AeroEclipse-VersaPAP nebulizer group. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments of a 10% NAC (3 mL) and 2.5 mg albuterol (0.5mL) inhalation solution separated by 4 hours, via the nebulization method specific to their group.
Frequently Asked Questions
What is The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)?
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) is a clinical trial registered under NCT06152653. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT06152653?
The current status of NCT06152653 (The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)) is: ACTIVE_NOT_RECRUITING.
When did The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) start?
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) started on 2024-04-09.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.